Chitosan-coated PLGA nanoparticles for the nasal delivery of ropinirole hydrochloride: In vitro and ex vivo evaluation of efficacy and safety

Chatzitaki, Aikaterini-Theodora; Jesus, Sandra; Karavasili, Christina; Andreadis, Dimitrios; Fatouros, Dimitrios G.; Borges, Olga

doi:10.1016/j.ijpharm.2020.119776

Cited by 82 publications

(59 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liu et al [58] developed a PLGA NP drug delivery system modified with angiopep-2 (RMT) and 1, 2-Dioleoyl-3-trimethylammonium-propane (AMT), for gefitinib and Golgi phosphoprotein 3 for the treatment of glioblastoma. Intranasal [59][60][61] or subcutaneous [62] administration of PLGA NP drug systems can bypass the BBB and avoid issues associated with systemic administration.…”

Section: Plga Nps Modifications and Mechanismsmentioning

confidence: 99%

PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP

et al. 2021

View full text Add to dashboard Cite

The blood–brain barrier (BBB) is a natural obstacle for drug delivery into the human brain, hindering treatment of central nervous system (CNS) disorders such as acute ischemic stroke, brain tumors, and human immunodeficiency virus (HIV)-1-associated neurocognitive disorders. Poly(lactic-co-glycolic acid) (PLGA) is a biocompatible polymer that is used in Food and Drug Administration (FDA)-approved pharmaceutical products and medical devices. PLGA nanoparticles (NPs) have been reported to improve drug penetration across the BBB both in vitro and in vivo. Poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), and poloxamer (Pluronic) are widely used as excipients to further improve the stability and effectiveness of PLGA formulations. Peptides and other linkers can be attached on the surface of PLGA to provide targeting delivery. With the newly published guidance from the FDA and the progress of current Good Manufacturing Practice (cGMP) technologies, manufacturing PLGA NP-based drug products can be achieved with higher efficiency, larger quantity, and better quality. The translation from bench to bed is feasible with proper research, concurrent development, quality control, and regulatory assurance.

show abstract

Section: Plga Nps Modifications and Mechanismsmentioning

confidence: 99%

PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The physical stability of RH‐loaded nanoformulations was conducted by monitoring changes in the hydrodynamic diameter of the nanoparticles via DLS measurements over 40 days period during storage at 25 °C ± 0.2 °C. [ 10 ] Measurements were carried out periodically after dilution of the aqueous NP suspensions in milli‐Q water. Each experiment was repeated in triplicate and the data were given as mean values ± standard deviation (SD).…”

Section: Methodsmentioning

confidence: 99%

Biocompatible mucoadhesive nanoparticles for brain targeting of ropinirole hydrochloride: Formulations, radiolabeling and biodistribution

2022

View full text Add to dashboard Cite

Two nanoformulations with mucoadhesive properties and brain-targeting mechanisms were designed to deliver the anti-Parkinson's drug, ropinirole hydrochloride (RH). In the first formulation, RH and the amphiphilic block copolymer methoxy poly(ethylene glycol)b-poly(caprolactone) were assembled in a core-shell morphology followed by coating with a mucoadhesive chitosan outer layer producing a multilayer vehicle (MLV). In the second formulation, RH was encapsulated during the polyelectrolyte complexation of two natural polymers, chitosan and alginate producing RH-loaded chitosan-alginate polyelectrolyte (PEC) nanocomplex. Conditions of each formulation were adopted for optimal drug loading. Physico-chemical characterization of the prepared formulations (particle size, polydispersity index and zeta-potential) exhibited stable monodispersed nanoparticles. RH was radiolabeled by I-131 radiotracer in a high-radiochemical yield.Biodistribution and brain targeting of RH from the prepared formulations were studied after administration of 131 I-RH-loaded nanoparticles to albino mice via intranasal and intravenous routs. Elevated brain radioactivity was detected post IN administration of ( 131 I-RH/PCL-PEG/CS) nanoparticles and ( 131 I-RH/CS-ALG) nanoparticles comparing with the IN administrated RH solutions (C max = 2.8 ± 0.3, 2 ± 0.3, 0.93 ± 0.03% radioactivity/g, 1 h post administration, respectively). This demonstrated that a relatively highbrain targeting could be achieved via intranasal route of administration of RH-loaded nanoparticles. The proposed models are further potential for application to deliver many other brain-targeting therapeutics.

show abstract

“…Ropinirole hydrochloride (RH) is a non-ergoline agonist that acts on D2-and D3-receptors in the brain. Chatzitaki et al [187] developed a PLGA and PLGA/CS NPs with mucoadhesive properties able to encapsulate RH and suitable to promote RH delivery across the nasal mucosa. RH-loaded PLGA/CS NPs showed a complete release of the drug in a simulated nasal electrolyte solution (SNES) throughout 24 h. In addition, they increased the permeation of RH through sheep nasal mucosa by 3.22-fold in comparison to PLGA NPs.…”

Section: Nose To Brain Deliverymentioning

confidence: 99%

Advances in Chitosan-Based Nanoparticles for Drug Delivery

Mikušová

Mikuš

2021

IJMS

295

120

View full text Add to dashboard Cite

Nanoparticles (NPs) have an outstanding position in pharmaceutical, biological, and medical disciplines. Polymeric NPs based on chitosan (CS) can act as excellent drug carriers because of some intrinsic beneficial properties including biocompatibility, biodegradability, non-toxicity, bioactivity, easy preparation, and targeting specificity. Drug transport and release from CS-based particulate systems depend on the extent of cross-linking, morphology, size, and density of the particulate system, as well as physicochemical properties of the drug. All these aspects have to be considered when developing new CS-based NPs as potential drug delivery systems. This comprehensive review is summarizing and discussing recent advances in CS-based NPs being developed and examined for drug delivery. From this point of view, an enhancement of CS properties by its modification is presented. An enhancement in drug delivery by CS NPs is discussed in detail focusing on (i) a brief summarization of basic characteristics of CS NPs, (ii) a categorization of preparation procedures used for CS NPs involving also recent improvements in production schemes of conventional as well as novel CS NPs, (iii) a categorization and evaluation of CS-based-nanocomposites involving their production schemes with organic polymers and inorganic material, and (iv) very recent implementations of CS NPs and nanocomposites in drug delivery.

show abstract

Chitosan-coated PLGA nanoparticles for the nasal delivery of ropinirole hydrochloride: In vitro and ex vivo evaluation of efficacy and safety

Cited by 82 publications

References 46 publications

PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP

PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP

Biocompatible mucoadhesive nanoparticles for brain targeting of ropinirole hydrochloride: Formulations, radiolabeling and biodistribution

Advances in Chitosan-Based Nanoparticles for Drug Delivery

Contact Info

Product

Resources

About